In the following video, Fool contributor Matt Thalman discusses how he plays the pharmaceutical industry. While the likes of Pfizer (NYSE:PFE) and Merck (NYSE:MRK) may be the first names that come to mind, Matt doesn't think they're the best investing choices, as he thinks the major drug companies don't offer the correct amount of reward to compensate for their risk.
That's why Matt prefers generic pharmaceutical companies. Mylan Pharmaceuticals (NASDAQ:MYL) and Teva Pharmaceutical Industries (NYSE:TEVA) are two of the big names in this market, and Matt says investors might consider looking here for a combination of less long-term risk but a strong potential for good returns.
The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
What Happened in the Stock Market Today
On a day stocks bounced up and down, shares of Energizer Holdings rose on acquisition news, and Merck reported positive results in a lung cancer trial.
These 3 Dividend Giants Are Safer Than You Think
Concerns about these stocks and their dividends are overblown.
Why 2017 Was a Year to Forget for Merck & Co. Inc.
Everything looked OK for the drugmaker until Merck delivered an unwelcome October surprise.